Business Monitor International


Qatar Pharmaceuticals & Healthcare Report

Published 15 October 2014

  • 97 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Qatar Pharmaceuticals & Healthcare Report

BMI View:   The reduction of a large number of medicine prices in Qatar is likely to be detrimental to pharmaceutical companies' revenue potential. New drug pricing - which was previously very high in the country - will increase the volume of sales, as medicines will become more affordable, partially counteracting losses from price reduction. Economic and political stability, in addition to projected growth in the pharmaceutical and healthcare markets, will ensure that Qatar remains a small but attractive market.

Headline Expenditure Projections

  • Pharmaceuticals: QAR1.63bn (USD449mn) in 2013 to QAR1.84bn (USD504mn) in 2014; +12.4% in local currency and 12.4% in US dollar terms. Forecast slightly higher than in Q314.

  • Healthcare: QAR17.06bn (USD4.69bn) in 2013 to QAR18.84bn (USD5.17bn) in 2014; +10.4% in both local currency and US dollar terms. Forecast revised upwards due to macroeconomic modifications.

Risk/Reward Rating: Qatar's risks are particularly low in comparison with the rest of the MEA region, although its potential rewards are dampened by the small market size. Nevertheless, Qatar's high level of urbanisation, rapid population growth and rising prevalence of chronic lifestyle diseases creates an environment in which there is strong potential for market growth. On account of shifts within BMI's Pharmaceutical Risk/Reward Rating Index for the Middle East and Africa matrix in Q414, Qatar has moved again down two positions in the MEA matrix to seventh place with the country's scores this quarter remaining 53.5 out of 100.

Key Trends And Developments

In August 2014, the Qatar National Research Fund (QNRF) will spend 24% of its funding on healthcare and medical research, focussing on diabetes, cancer and heart disease, reports Qatar Health magazine, citing Director Abdul Sattar Al Taie. 'This will help Qatar build research capacity by interacting with researchers around the world and build research culture,' said Al Taie, reports...

Table of Contents

BMI Industry View
7
SWOT
10
Political
12
Economic
13
Business Environment
14
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Qatar 2010-2018)
20
Healthcare Market Forecast
21
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Qatar 2010-2018)
23
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Qatar 2010-2018)
23
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Qatar 2010-2018)
23
Prescription Drug Market Forecast
24
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Qatar 2010-2018)
25
Patented Drug Market Forecast
25
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Qatar 2010-2018)
26
Generic Drug Market Forecast
27
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Qatar 2010-2018)
28
OTC Medicine Market Forecast
29
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Qatar 2010-2018)
30
Pharmaceutical Trade Forecast
31
Table: Pharmaceutical Trade Data And Forecasts (Qatar 2012-2018)
32
Table: Pharmaceutical Trade Data And Forecasts local currency (Qatar 2012-2018)
32
Other Healthcare Data
33
Table: Healthcare Professionals (2009)
34
Key Risks To BMI's Forecast Scenario
35
Macroeconomic Forecasts
37
Industry Risk Reward Ratings
47
Middle East & Africa Risk/Reward Index
47
Qatar Risk/Reward Ratings
54
Rewards
54
Risks
55
Market Overview
56
Industry Trends And Developments
57
Epidemiology
57
Healthcare Sector
62
Healthcare Sector Developments
63
Health Insurance
66
Healthcare IT
67
Research & Development
68
Clinical Trials
70
Regulatory Development
71
Regional Regulatory Developments
72
Intellectual Property Regime
75
Pricing And Reimbursement Regime
75
Competitive Landscape
78
Pharmaceutical Industry
78
Pharmaceutical Wholesale And Retail
79
Company Profile
81
Medicare Group
81
Ebn Sina Medical
83
Qatar Pharma
85
Novartis
87
Merck & Co
89
GlaxoSmithKline
91
Pfizer
93
Demographic Forecast
95
Table: Qatar's Population By Age Group, 1990-2020 ('000)
96
Table: Qatar's Population By Age Group, 1990-2020 (% of total)
97
Table: Qatar's Key Population Ratios, 1990-2020
98
Table: Qatar's Rural And Urban Population, 1990-2020
98
Glossary
99
Methodology
101
Pharmaceutical Expenditure Forecast Model
101
Healthcare Expenditure Forecast Model
101
Notes On Methodology
102
Risk/Reward Ratings Methodology
103
Ratings Overview
104
Table: Pharmaceutical Risk/Reward Ratings Indicators
104
Indicator Weightings
105

The Qatar Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Qatar Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Qatari pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Qatar to test other views - a key input for successful budgeting and strategic business planning in the Qatari pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Qatari pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Qatar.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc